Navigation Links
Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing

MOUNTAIN VIEW, Calif., June 12, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced a 10-for-1 reverse split of its common stock.  The reverse stock split became effective today at 5:01 p.m. Eastern Time and Alexza's common stock will begin trading on The NASDAQ Global Market on a split-adjusted basis when the market opens on Wednesday, June 13, 2012.   

At the effective time of the reverse stock split, every ten shares of Alexza's issued and outstanding common stock converted automatically into one issued and outstanding share of common stock, without any change in the par value per share.  The reverse stock split reduced the number of shares of Alexza's common stock outstanding from approximately 119.6 million to approximately 12.0 million.  In addition, the reverse stock split effected a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise or settlement of all outstanding options, restricted stock units and warrants to purchase or acquire shares of Alexza's common stock, and the number of shares reserved for issuance pursuant to Alexza's existing equity incentive and employee stock purchase plans were reduced proportionately.  No fractional shares will be issued as a result of the reverse stock split, and stockholders who otherwise would be entitled to a fractional share will receive, in lieu thereof, a cash payment based on the closing sale price of the Alexza's common stock as reported today on the NASDAQ Global Market.  Alexza's transfer agent will provide instructions to stockholders regarding the process for exchanging shares.  Additional information regarding the reverse stock split can be found in Alexza's definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2012. 

The purpose of the reverse stock split is to raise the per share trading price of Alexza's common stock to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Global Market.  As previously disclosed, in order to maintain Alexza's listing on The NASDAQ Global Market, on or before July 30, 2012, the common stock must have a minimum closing bid price of $1.00 per share for a minimum of 10 prior consecutive trading days. There can be no assurance that the reverse stock split will have the desired effect of raising the closing bid price of Alexza's common stock prior to July 30, 2012 to meet this requirement.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  With the Staccato system, a drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE™ (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a complete response letter (CRL) from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010, a REMS guidance meeting with the FDA in April 2011, and the ADASUVE NDA was resubmitted in August 2011.  In December 2011, the ADASUVE NDA was the subject of an advisory committee meeting.  In January 2012, Alexza received notice of a 90-day extension of the PDUFA goal date, from February 4, 2012 to May 4, 2012.  On May 3, 2012, Alexza announced that it had received a second CRL from the FDA regarding the ADASUVE NDA.  Alexza is working to fully understand the specifics of the deficiencies and plans to resubmit the ADASUVE NDA as soon as possible.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit  ADASUVE™ is a registered trademark of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement

This news release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the company's expectations or beliefs, including any such statement about the effects of the reverse stock split, is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the Company's ability to raise additional funds and the potential terms of such potential financing, the Company's ability to maintain the listing of its common stock on The NASDAQ Global Market, the Company's plans to resubmit the ADASUVE NDA, the ability of the Company to address the issues raised in the May 2012 CRL, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
2. Alexza Receives Complete Response Letter for Adasuve™ NDA
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
5. IntegriChain® Announces Release of DNA 2.0
6. American HealthTech Announces Streamlined Connectivity With LTC Trend Tracker
7. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
8. Law Office of Brodsky & Smith, LLC Announces Investigation of SRI Surgical Express, Inc.
9. Forum Extended Care Services Announces Plans to Move to Larger, State-Of-the-art Facility
10. Nonin Medical, Inc. Announces U.S. Market Release of EQUANOX™ Advance Model 8004CB Series Sensor for Neonatal, Pediatric Patients
11. Hanger Orthopedic Group, Inc. announces name change to Hanger, Inc.
Post Your Comments:
(Date:10/12/2015)... Va. , Oct. 12, 2015  Today, Divurgent is ... of Advisory Services. As a former CIO, Paul brings 15 ... not just understand or sympathize with today,s CIOs, he is ... the same challenges Paul has faced, and his new role ... in ensuring technology efficiencies across an organization. ...
(Date:10/12/2015)... DENVER , Oct. 12, 2015 Beginning ... ICD-10 Codes. Therapy Partner, the fastest growing practice management ... automated technology that easily converts all patient diagnostic codes ... --> --> ... Brief for all mental health practitioners to easily understand ...
(Date:10/12/2015)... INDIANAPOLIS , Oct. 12, 2015 Eli ... ACCELERATE study,s academic leadership have accepted the recommendation of ... 3 trial of the investigational medicine evacetrapib, due to ... the treatment of high-risk atherosclerotic cardiovascular disease and will ... --> --> The independent data ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... have developed valuable new strategies for enrolling and serving insurance consumers who do ... obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: The ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... smoke-free communities, and the Florida Apartment Association (FAA) has partnered with the Florida ... communities meet the demand. , The FAA Smoke-Free Multifamily Housing Program launched ...
(Date:10/13/2015)... ... 13, 2015 , ... Just under three months ago, eMarketing Concepts ... promotion – effectively offering all of their services for just a buck in the ... flooded with phone calls from interested buyers. As a genuine one-stop-shop for internet marketing, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... a new PDF automation tool to batch conversions of CAD drawings, plans, ... 100% document fidelity. , CADConverter eliminates the complexity requirement of specialized applications to ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... The Bill ... in San Diego, also offering expert reconstruction and flood remediation services. Family-owned and operated ... They have been named the Best San Diego plumber two years in a row ...
Breaking Medicine News(10 mins):